Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine
Lung cancer is a major malignancy that poses a significant threat to human health, with its complex pathogenesis and molecular characteristics presenting substantial challenges for treatment. Traditional two-dimensional cell cultures and animal models are limited in their ability to accurately repli...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2025.1554268/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731621381472256 |
|---|---|
| author | Chaoxing Liu Chaoxing Liu Chaoxing Liu Chao Shi Chao Shi Chao Shi Siya Wang Rong Qi Rong Qi Rong Qi Weiguo Gu Weiguo Gu Weiguo Gu Feng Yu Feng Yu Guohua Zhang Feng Qiu Feng Qiu |
| author_facet | Chaoxing Liu Chaoxing Liu Chaoxing Liu Chao Shi Chao Shi Chao Shi Siya Wang Rong Qi Rong Qi Rong Qi Weiguo Gu Weiguo Gu Weiguo Gu Feng Yu Feng Yu Guohua Zhang Feng Qiu Feng Qiu |
| author_sort | Chaoxing Liu |
| collection | DOAJ |
| description | Lung cancer is a major malignancy that poses a significant threat to human health, with its complex pathogenesis and molecular characteristics presenting substantial challenges for treatment. Traditional two-dimensional cell cultures and animal models are limited in their ability to accurately replicate the characteristics of different lung cancer patients, thereby hindering research on disease mechanisms and treatment strategies. The development of organoid technology has enabled the growth of patient-derived tumor cells in three-dimensional cultures, which can stably preserve the tumor’s tissue morphology, genomic features, and drug response. There have been significant advancements in the field of patient-derived lung cancer organoids (PDLCOs), challenges remain in the reproducibility and standardization of PDLCOs models due to variations in specimen sources, subsequent processing techniques, culture medium formulations, and Matrigel batches. This review summarizes the cultivation and validation processes of PDLCOs and explores their clinical applications in personalized treatment, drug screening after resistance, PDLCOs biobanks construction, and drug development. Additionally, the integration of PDLCOs with cutting-edge technologies in various fields, such as tumor assembloid techniques, artificial intelligence, organoid-on-a-chip, 3D bioprinting, gene editing, and single-cell RNA sequencing, has greatly expanded their clinical potential. This review, incorporating the latest research developments in PDLCOs, provides an overview of their cultivation, clinical applications, and interdisciplinary integration, while also addressing the prospects and challenges of PDLCOs in precision medicine for lung cancer. |
| format | Article |
| id | doaj-art-03df51150b0744e29214e7a76f6c149d |
| institution | DOAJ |
| issn | 2296-634X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj-art-03df51150b0744e29214e7a76f6c149d2025-08-20T03:08:29ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-04-011310.3389/fcell.2025.15542681554268Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicineChaoxing Liu0Chaoxing Liu1Chaoxing Liu2Chao Shi3Chao Shi4Chao Shi5Siya Wang6Rong Qi7Rong Qi8Rong Qi9Weiguo Gu10Weiguo Gu11Weiguo Gu12Feng Yu13Feng Yu14Guohua Zhang15Feng Qiu16Feng Qiu17Department of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaNanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaLung cancer is a major malignancy that poses a significant threat to human health, with its complex pathogenesis and molecular characteristics presenting substantial challenges for treatment. Traditional two-dimensional cell cultures and animal models are limited in their ability to accurately replicate the characteristics of different lung cancer patients, thereby hindering research on disease mechanisms and treatment strategies. The development of organoid technology has enabled the growth of patient-derived tumor cells in three-dimensional cultures, which can stably preserve the tumor’s tissue morphology, genomic features, and drug response. There have been significant advancements in the field of patient-derived lung cancer organoids (PDLCOs), challenges remain in the reproducibility and standardization of PDLCOs models due to variations in specimen sources, subsequent processing techniques, culture medium formulations, and Matrigel batches. This review summarizes the cultivation and validation processes of PDLCOs and explores their clinical applications in personalized treatment, drug screening after resistance, PDLCOs biobanks construction, and drug development. Additionally, the integration of PDLCOs with cutting-edge technologies in various fields, such as tumor assembloid techniques, artificial intelligence, organoid-on-a-chip, 3D bioprinting, gene editing, and single-cell RNA sequencing, has greatly expanded their clinical potential. This review, incorporating the latest research developments in PDLCOs, provides an overview of their cultivation, clinical applications, and interdisciplinary integration, while also addressing the prospects and challenges of PDLCOs in precision medicine for lung cancer.https://www.frontiersin.org/articles/10.3389/fcell.2025.1554268/fulllung cancerorganoidscultivationclinical applicationstransforming |
| spellingShingle | Chaoxing Liu Chaoxing Liu Chaoxing Liu Chao Shi Chao Shi Chao Shi Siya Wang Rong Qi Rong Qi Rong Qi Weiguo Gu Weiguo Gu Weiguo Gu Feng Yu Feng Yu Guohua Zhang Feng Qiu Feng Qiu Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine Frontiers in Cell and Developmental Biology lung cancer organoids cultivation clinical applications transforming |
| title | Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine |
| title_full | Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine |
| title_fullStr | Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine |
| title_full_unstemmed | Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine |
| title_short | Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine |
| title_sort | bridging the gap how patient derived lung cancer organoids are transforming personalized medicine |
| topic | lung cancer organoids cultivation clinical applications transforming |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2025.1554268/full |
| work_keys_str_mv | AT chaoxingliu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT chaoxingliu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT chaoxingliu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT chaoshi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT chaoshi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT chaoshi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT siyawang bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT rongqi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT rongqi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT rongqi bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT weiguogu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT weiguogu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT weiguogu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT fengyu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT fengyu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT guohuazhang bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT fengqiu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine AT fengqiu bridgingthegaphowpatientderivedlungcancerorganoidsaretransformingpersonalizedmedicine |